Results 61 to 70 of about 148,335 (302)

Radiometal-Based PET/MRI Contrast Agents for Sensing Tumor Extracellular pH

Biosensors, 2022
Acidosis is a useful biomarker for tumor diagnoses and for evaluating early response to anti-cancer treatments. Despite these useful applications, there are few methods for non-invasively measuring tumor extracellular pH, and none are routinely used in ...
Alyssa C. Pollard, Jorge de la Cerda, F. William Schuler, Tyler R. Pollard, Aikaterini Kotrotsou, Federica Pisaneschi, Mark D. Pagel   +6 more
doaj   +1 more source

FDG-PET imaging for the evaluation of antiglioma agents in a rat model [PDF]

Neuro-Oncology, 2008
The increasing development of novel anticancer agents demands parallel advances in the methods used to rapidly assess their therapeutic efficacy (TE) in the preclinical phase. We evaluated the ability of small-animal PET, using the (18)F-fluoro-deoxy-D-glucose (FDG) radiotracer, to predict the TE of a number of anticancer agents in the rat C6 glioma ...
Sarah, Assadian, Antonio, Aliaga, Rolando F, Del Maestro, Alan C, Evans, Barry J, Bedell   +4 more
openaire   +2 more sources

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Radiology [PDF]

, 2004
Radiology is the fastest developing field of medicine and these unprecedented advances have been mainly due to improving computer technology. Digital imaging is a technology whereby images are acquired in a computer format, so that they can be easily ...
Vassallo, Pierre
core  

Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. [PDF]

, 2016
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells.
Chen, Chang-Po, Kumar, Pardeep, Mehta, Neil, Paudyal, Bishnuhari, Thakur, Mathew L., Tripathi, Sushil Kumar, Wickstrom, Eric   +6 more
core   +2 more sources

A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma

Scientific Reports
Adenoid cystic carcinoma (ACC) is a rare malignancy of the salivary glands with poor long-term outcomes and with a need for improved imaging and therapeutic options.
Andrew F. Voter, Alireza Amindarolzarbi, Colette J. Shen, Jarey Wang, Hyunseok Kang, Rajni Sharma, Lilja B. Solnes, Martin G. Pomper, Justin A. Bishop, Steven P. Rowe, Ana P. Kiess   +10 more
doaj   +1 more source

Imaging Alzheimer's disease pathophysiology with PET

Dementia & Neuropsychologia
Alzheimer's disease (AD) has been reconceptualised as a dynamic pathophysiological process characterized by preclinical, mild cognitive impairment (MCI), and dementia stages.
Lucas Porcello Schilling, Eduardo R. Zimmer, Monica Shin, Antoine Leuzy, Tharick A. Pascoal, Andréa L. Benedet, Wyllians Vendramini Borelli, André Palmini, Serge Gauthier, Pedro Rosa-Neto   +9 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Evaluations of the performances of PET and MRI in a simultaneous PET/MRI instrument for pre-clinical imaging

EJNMMI Physics, 2022
Background PET/MRI is an attractive imaging modality due to the complementary nature of MRI and PET. Obtaining high quality small animal PET/MRI results is key for the translation of novel PET/MRI agents and techniques to the radiology clinic.
Alyssa C. Pollard, Jorge de la Cerda, F. William Schuler, Charles V. Kingsley, Seth T. Gammon, Mark D. Pagel   +5 more
doaj   +1 more source

Applying aryltrifluoroborates as PET imaging agents

, 2013
This dissertation is focused on applying aryltrifluoroborates (ArBF₃s) as PET imaging agents. Several aspects of this new ¹⁸F-labeling technique are addressed. These include the hydrolytic stability of heteroaryltrifluoroborates (HetArBF₃s), the fluoridation of arylboronic acids/esters and the radiosyntheses of several ¹⁸F-ArBF₃ labeled biomolecules ...
openaire   +1 more source